New follicular lymphoma study findings have been reported from Sanofi Pasteur
2009 JUN 29 - (NewsRx.com) -- According to recent research from Toronto, Canada, "We enrolled 23 patients with relapsed follicular lymphoma (FL) in a prospective single-arm study of auto-SCT combined with in vivo rituximab graft purging and post transplant rituximab maintenance. Minimal residual disease was monitored with quantitative PCR testing." "With a median follow-up of 74.2 months, neither median overall survival (OS) nor PFS has been reached. Here, 5-year OS and 5-year PFS are 78% (95% confidence interval (CI) 61-95%) and 59% ( 95% CI 38-80%), respectively. Time to progression (TTP) with the experimental regimen was significantly improved compared with TTP with the last prior treatment (P <0.001). Durable molecular remissions occurred in 11 of 13 assessable patients. PFS was significantly longer in patients who achieved a molecular remission by 3 months post-auto-SCT (P = 0.001). Prolonged hypogammaglobulinemia occurred in most patients; however, no increase in major infections was observed," wrote L.K. Hicks and colleagues, Sanofi Pasteur. The researchers concluded: "Bone Marrow Transplantation (2009) 43, 701-708; doi:10.1038/bmt.2008.382; published online 24 November 2008." Hicks and colleagues published their study in Bone Marrow Transplantation (Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplantation, 2009;43(9):701-708). For additional information, contact N.L. Berinstein, Sanofi Pasteur, 1755 Steeles Avenue W, Toronto, ON M2R 3T4, Canada. Publisher contact information for the journal Bone Marrow Transplantation is: Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England. Keywords: Canada, Toronto, Agammaglobulinemia, Biotechnology, Bone Marrow Transplantation, Follicular Lymphoma, Hematology, Medical Device, Monoclonal Antibodies, Oncology, Pharmaceutical Business, Pharmaceutical Company, Residual Neoplasm, Sanofi Pasteur, Surgery, Sanofi Pasteur. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
